2026-06-14T03:54:57Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/188582024-02-27T15:24:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Molina-Ramos, Ana I author Gómez-Moyano, Elisabeth author Rodríguez-Capitán, Jorge author Angullo-Gómez, María author Gallardo-Jiménez, Patricia author Pérez de Pedro, Iván author Valiente de Santis, Lucía author Pérez-Villardón, Beatriz author Piñero-Uribe, Isabel author Mora-Robles, Javier author Becerra-Muñoz, Víctor Manuel author Jiménez-Navarro, Manuel author 2022-11-26 The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines. 10.3390/jcm11236999 2077-0383 Journal of clinical medicine http://hdl.handle.net/10668/21365 36498573 http://hdl.handle.net/20.500.12105/18858 COVID-19 mRNA vaccines myocarditis Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination.